Sign In
Buy NTLA
$15.25
-0.500 (-3.17%)
At Close: Jun 23, 2026
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
11:02am, Saturday, 20'th Jun 2026
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FD
Dow Extends Record Run as Fed Decision Looms
12:03pm, Wednesday, 17'th Jun 2026
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
02:30am, Wednesday, 17'th Jun 2026
There could be additional catalysts for this drugmaker over the next year.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
11:20am, Tuesday, 16'th Jun 2026
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
09:45am, Tuesday, 16'th Jun 2026
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
09:39am, Monday, 15'th Jun 2026
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based tre
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
12:31pm, Wednesday, 10'th Jun 2026
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Jun 2026
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
08:45am, Sunday, 31'st May 2026
Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack r
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
03:36pm, Wednesday, 27'th May 2026
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
12:56pm, Tuesday, 19'th May 2026
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:40pm, Tuesday, 12'th May 2026
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
12:47pm, Tuesday, 12'th May 2026
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
